A smartphone-based enzyme-linked immunochromatographic sensor for rapid quantitative detection of carcinoembryonic antigen

Wu, Ze; Lu, Jinhui; Fu, Qiangqiang; Sheng, Lianghe; Liu, Bochao; Li, Chengyao

doi:10.1016/j.snb.2020.129163

Cited by 36 publications

(17 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While on the one hand the use of readers increases the cost per analysis, on the other it allows data digitalization, tracking, storage, and transmission reducing interpretation and transcription errors, thus ensuring testing quality and control [ 18 ]. In this sense, we are also witnessing an increasing exploitation of the built-in smartphone technology to be used as LFIA reader, as increasingly reported in the literature [ 122 , 132 , 267 , 268 , 269 , 270 , 271 , 272 , 273 , 274 , 275 ]. Moreover, the use of strip readers paved the way for the use of alternative detection methods (fluorescence, chemiluminescence, etc.)…”

Section: Evergreen and New Challengesmentioning

confidence: 99%

Ten Years of Lateral Flow Immunoassay Technique Applications: Trends, Challenges and Future Perspectives

Nardo

Chiarello

Cavalera

et al. 2021

Sensors

256

162

View full text Add to dashboard Cite

The Lateral Flow Immunoassay (LFIA) is by far one of the most successful analytical platforms to perform the on-site detection of target substances. LFIA can be considered as a sort of lab-in-a-hand and, together with other point-of-need tests, has represented a paradigm shift from sample-to-lab to lab-to-sample aiming to improve decision making and turnaround time. The features of LFIAs made them a very attractive tool in clinical diagnostic where they can improve patient care by enabling more prompt diagnosis and treatment decisions. The rapidity, simplicity, relative cost-effectiveness, and the possibility to be used by nonskilled personnel contributed to the wide acceptance of LFIAs. As a consequence, from the detection of molecules, organisms, and (bio)markers for clinical purposes, the LFIA application has been rapidly extended to other fields, including food and feed safety, veterinary medicine, environmental control, and many others. This review aims to provide readers with a 10-years overview of applications, outlining the trends for the main application fields and the relative compounded annual growth rates. Moreover, future perspectives and challenges are discussed.

show abstract

Section: Evergreen and New Challengesmentioning

confidence: 99%

Ten Years of Lateral Flow Immunoassay Technique Applications: Trends, Challenges and Future Perspectives

Nardo

Chiarello

Cavalera

et al. 2021

Sensors

256

162

View full text Add to dashboard Cite

show abstract

“…The appropriate cut-off value of this system was set as a mean value of negative control plus 2 SD. The LOD was defined as the lowest level of NP standard which was tested higher than the cut-off value of this system ( Wu et al, 2021 ). Thus, the LOD of this system for detecting the NP standard was 10 pg/mL and the linear range of SP-NLISA was 30 pg/mL–3 ng/mL ( Figures 4A,B ).…”

Section: Resultsmentioning

confidence: 99%

“…The appropriate cut-off value of this system was set as a mean value of negative control plus 2 SD. The LOD was defined as the lowest level of NP standard which was tested higher than the cut-off value of this system (Wu et al, 2021). Thus, the LOD FIGURE 5 | The clinical samples of COVID-19 patients were tested by SP-NLISA.…”

Section: Measurement Of Np By Sp-nlisamentioning

confidence: 99%

Development of a Smartphone-Based Nanozyme-Linked Immunosorbent Assay for Quantitative Detection of SARS-CoV-2 Nucleocapsid Phosphoprotein in Blood

Liu

Liang

et al. 2021

Front. Microbiol.

Self Cite

View full text Add to dashboard Cite

Since December 2019, a novel coronavirus (SARS-CoV-2) has resulted in a global pandemic of coronavirus disease (COVID-19). Although viral nucleic acid test (NAT) has been applied predominantly to detect SARS-CoV-2 RNA for confirmation diagnosis of COVID-19, an urgent need for alternative, rapid, and sensitive immunoassays is required for primary screening of virus. In this study, we developed a smartphone-based nanozyme-linked immunosorbent assay (SP-NLISA) for detecting the specific nucleocapsid phosphoprotein (NP) of SARS-CoV-2 in 37 serum samples from 20 COVID-19 patients who were diagnosed by NAT previously. By using SP-NLISA, 28/37 (75.7%) serum samples were detected for NP antigens and no cross-reactivity with blood donors’ control samples collected from different areas of China. In a control assay using the conventional enzyme-linked immunosorbent assay (ELISA), only 7/37 (18.91%) serum samples were detected for NP antigens and no cross-reactivity with control samples. SP-NLISA could be used for rapid detection of SARS-CoV-2 NP antigen in primary screening of SARS-CoV-2 infected individuals.

show abstract

“…In comparison with Au@PtNPs, natural protease, such as horseradish peroxidase (HRP), has low storage stability, complicated preparation process, and lower sensitivity. [30] , [31] , [32] …”

Section: Introductionmentioning

confidence: 99%

A nanoenzyme linked immunochromatographic sensor for rapid and quantitative detection of SARS-CoV-2 nucleocapsid protein in human blood

Liang

Liu

et al. 2021

Sensors and Actuators B: Chemical

Self Cite

View full text Add to dashboard Cite

The establishment of a simple, low-cost, high-sensitive and rapid immunoassay for detecting SARS-CoV-2 antigen in human blood is an effective mean of discovering early SARS-CoV-2 infection and controlling the pandemic of COVID-19. Herein, a smartphone based nanozyme linked immunochromatographic sensor (NLICS) for the detection of SARS-CoV-2 nucleocapsid protein (NP) has been developed on demand. The system is integrated by disposable immunochromatography assay (ICA) and optical sensor devices. Immunoreaction and enzyme-catalyzed substrate color reaction were carried out on the chromatographic strip in a device, of which the light signal was read by a photometer through a biosensor channel, and the data was synchronously transmitted via the Bluetooth to the app in-stored smartphone for reporting the result. With a limit of detection (LOD) of 0.026 ng/mL NP, NLICS had the linear detection range (LDR) between 0.05 and 1.6 ng/mL NP, which was more sensitive than conventional ICA. NLICS took 25 min for reporting results. For detection of NP antigen in clinical serum samples from 21 COVID-19 patients and 80 healthy blood donor controls, NLICS and commercial enzyme linked immunosorbent assay (ELISA) had 76.2% or 47.6% positivity, and 100% specificity, respectively ( P =0.057), while a good correlation coefficient (r=0.99) for quantification of NP between two assays was obtained. In conclusion, the NLICS was a rapid, simple, cheap, sensitive and specific immunochromatographic sensing assay for early diagnosis of SARS-CoV-2 infection.

show abstract

A smartphone-based enzyme-linked immunochromatographic sensor for rapid quantitative detection of carcinoembryonic antigen

Cited by 36 publications

References 23 publications

Ten Years of Lateral Flow Immunoassay Technique Applications: Trends, Challenges and Future Perspectives

Ten Years of Lateral Flow Immunoassay Technique Applications: Trends, Challenges and Future Perspectives

Development of a Smartphone-Based Nanozyme-Linked Immunosorbent Assay for Quantitative Detection of SARS-CoV-2 Nucleocapsid Phosphoprotein in Blood

A nanoenzyme linked immunochromatographic sensor for rapid and quantitative detection of SARS-CoV-2 nucleocapsid protein in human blood

Contact Info

Product

Resources

About